Patents Examined by Lynn A. Bristol
  • Sialyl-di-Lewisas expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
    Patent number: 10835618
    Abstract: The present invention relates to an isolated specific binding member capable of binding sialyl-di-Lewisa, and associated treatments and pharmaceutical compositions for treatment of cancer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Inventors: Lindy Gillian Durrant, Mireille Vankemmelbeke, Silvana Tivadar, Tina Parsons, Richard McIntosh
  • PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
    Patent number: 10815304
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 27, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
    Patent number: 10793641
    Abstract: The present invention provides fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: October 6, 2020
    Assignee: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Huamao Wang, Bo Song, Peng Wang
  • Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
    Patent number: 10793632
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 6, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Bispecific checkpoint inhibitor antibodies
    Patent number: 10787518
    Abstract: The present invention is directed to compositions that include programmed cell death 1 (PD-1) binding domains and antibodies that include such PD-1 binding domains. Also provided are nucleic acid compositions that encode the binding domains and antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: September 29, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
  • MND promoter chimeric antigen receptors
    Patent number: 10774343
    Abstract: Vector compositions comprising a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a chimeric antigen receptor (CAR) are provided.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: September 15, 2020
    Assignee: bluebird bio, Inc.
    Inventors: Richard Morgan, Kevin Friedman, Byoung Ryu
  • IgG bispecific antibodies and processes for preparation
    Patent number: 10774156
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 15, 2020
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Anti-TIGIT antibodies
    Patent number: 10766957
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 8, 2020
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • Combination of oncolytic virus with immune checkpoint modulators
    Patent number: 10765710
    Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising an oncolytic virus and one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of an oncolytic virus and one or more immune checkpoint modulator(s).
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 8, 2020
    Assignees: Institut Gustave-Roussy, Transgene SA
    Inventors: Laurence Zitvogel, Xavier Preville, Laetitia Fend
  • Anti-C10ORF54 antibodies and uses thereof
    Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Antibody light chains
    Patent number: 10738103
    Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 11, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Roland Beckmann
  • Anti-PD-1 antibodies and their uses
    Patent number: 10730953
    Abstract: The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 4, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Daniel E. H. Afar, Fiona A. Harding, Josue Samayoa
  • MSLN targeting trispecific proteins and methods of use
    Patent number: 10730954
    Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: August 4, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
    Patent number: 10731128
    Abstract: The described invention provides a method for in vitro immunoactivation of mononuclear cells by contact with one or more populations of engineered leukocyte stimulator cells genetically engineered to express a core of 3 essential immunomodulator peptides, and optionally additional R immunomodulator peptides, and use of a cell product comprising the expanded and activated mononuclear cell population comprising one or more subpopulations of cytotoxic serial killer cells for passive immunization of a cancer patient not currently under the influence of an immunosuppressive regimen.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 4, 2020
    Assignee: ALLOPLEX BIOTHERAPEUTICS, INC.
    Inventor: Frank Borriello
  • Antibody molecules to LAG-3 and uses thereof
    Patent number: 10711060
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 14, 2020
    Assignees: NOVARTIS AG, Immutep S.A.S.
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Human monoclonal antibodies against CD25
    Patent number: 10703818
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 7, 2020
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • Anti-PD-L1 antibodies
    Patent number: 10696745
    Abstract: The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 30, 2020
    Inventors: Yong Zheng, Jing Li, Zhisheng Chen
  • Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
    Patent number: 10688180
    Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: June 23, 2020
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMA
    Inventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
  • Human IgG1 derived antibody with pro-apoptotic activity
    Patent number: 10669328
    Abstract: A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1?1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1?1 domain by the CH1 domain from a human IgG2 (CH1?2), IgG3 (CH1?3) or IgG4 (CH1?4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (?)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: June 2, 2020
    Assignee: OGD2 PHARMA
    Inventors: Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
  • Antigen-binding constructs that bind to and inhibit catalase and/or superoxide dismutase as well as pharmaceutical compositions containing them for tumor therapy
    Patent number: 10669350
    Abstract: The invention relates to single domain VHH fragments which specifically bind to and inhibit superoxide dismutase and/or bind to and inhibit catalase and/or bind to and inhibit superoxide dismutase and catalase, in particular for the use in the therapy of tumor diseases.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: June 2, 2020
    Inventors: Georg Bauer, Manfred Motz